Pharma

Your Article Summary

See Latest Articles

Everolimus (Afinitor): Antineoplastic agent approved for the treatment of advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib
Formulary , 05/19/09

Everolimus is an antineoplastic agent that inhibits mammalian target of rapamycin, thus reducing cell proliferation, angiogenesis, and glucose uptake. This agent was approved on March 2009, for the treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Novartis gains rights to two oral targeted investigational therapies focusing on patients with life-threatening blood disorders and cancers
Novartis, 11/30/09

Major European regulatory milestone in cardiovascular protection for Micardis : Now approved by the European Commission to reduce the risk of cardiovascular (CV) morbidity in high CV risk patients
Boehringer Ingelheim, 11/30/09

Human genome sciences submits biologics license application to fda for zalbin
Human Genome Sciences, 11/30/09

 See all of Drug/Product Approvals